glesatinib glesatinib glesatinib (mgcd265) is an experimental anti-cancer drug. glesatinibclinical dataroutes ofadministrationby mouthatc codenonelegal statuslegal status investigational identifiers iupac name n-methyl}-2-pyridinyl)thienopyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide cas number936694-12-1pubchem cid25181472chemspider52084900unii7q29oxd98nkeggd11136chemical and physical dataformulac31h27f2n5o3s2molar mass619.71 g·mol−13d model (jsmol)interactive image smiles coccncc1ccc(nc1)c2cc3c(s2)c(ccn3)oc4ccc(cc4f)nc(=s)nc(=o)cc5ccc(cc5)f inchi inchi=1s/c31h27f2n5o3s2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34h,12-14,17h2,1h3,(h2,37,38,39,42)key:yrchyhrcbxnynu-uhfffaoysa-n it is in phase 2 clinical trials for non-small cell lung cancer (nsclc). it is a spectrum selective tyrosine kinase inhibitor "for the treatment of non-small cell lung cancer (nsclc) patients with genetic alterations of met".